Pseudomyxoma peritonei (PMP) is a rare condition of mucinous ascites associated mainly with mucinous tumors of appendix or ovary. PMP often recurs after treatment and may eventually cause death by abdominal visceral dysfunction via compression with mucinous ascites. Although radical peritonectomy and hyperthermic intra-peritoneal chemotherapy are becoming popular globally, the optimal treatment of PMP has not been established in Japan. We conducted a retrospective multicenter study to clarify the optimal treatment and the prognostic factors of PMP. A total of 23 patients with PMP were analyzed in the Tohoku Gynecologic Cancer Unit (TGCU). Clinical and follow-up data were retrieved and a central pathology review was performed. The median follow-up period was 46 months. Eleven patients underwent complete resection. There were 7 deaths out of 13 recurrences/progressions in this period. All the recurrence/ progression was confined to the abdomen. Unexpectedly, neither radical peritonectomy nor hyperthermic intra-peritoneal chemotherapy had been performed, indicating that both radical peritonectomy and hyperthermic intra-peritoneal chemotherapy are not yet popular in Japan. The medians of overall survival and disease-free period were 166 months and 30 months, respectively. Univariate and multivariate analyses revealed that the only prognostic factor was macroscopic residual tumor (P = 0.022). Although chemotherapy was not a prognostic factor (P = 0.16), those who received intra-peritoneal chemotherapy tended to have a better prognosis than those who received systemic or no chemotherapy (P = 0.064). In conclusion, the macroscopic residual tumor is an important prognostic factor in Japanese patients with PMP.
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Keywords: pseudomyxoma peritonei; retrospective multicenter study; clinico-pathological analysis; prognostic factors; intraperitoneal chemotherapy Tohoku J. Exp. Med., 2011, 223 (2), 91-96. © 2011 Tohoku University Medical Press Pseudomyxoma peritonei (PMP) is defined as a condition characterized by the accumulation of abundant mucinous material within the peritoneal cavity, often accompanied by an ovarian or gastrointestinal tumor. It often recurs after treatment and uncontrolled PMP can eventually cause death by dysfunctional abdominal viscera caused by compression with mucinous ascites. It is a rare condition that occurs in women, with an estimated incidence of 2 per 10,000 laparotomies (Mann et al. 1990 ) or 1-2 per million inhabitants per year (Smeenk et al. 2008) . PMP is now considered to be of appendiceal origin (Ronnet et al. 2004 ). However, gynecologists often treat PMP under the diagno-sis of ovarian tumor, because about 39% of women with PMP have an ovarian tumor (Esquivel and Sugarbaker 2000) . Although a combination of radical peritonectomy (RP) and hyperthermic intra-peritoneal chemotherapy (HIPEC), so-called Sugarbaker's method (Sugarbaker 1995 (Sugarbaker , 2006 , is becoming popular globally, the optimal treatment of PMP has not been established in Japan.
To the best of our knowledge, there is only one clinicopathological study on Japanese patients with PMP (Kataoka et al. 1989) . The purpose of this study is to investigate the current treatment realities of PMP and its prognostic factors in Japan.
Methods
This is a retrospective multicenter analysis of PMP patients who were treated by gynecologic oncologists from the Tohoku Gynecologic Cancer Unit (TGCU). The TGCU consists of a tertiary center hospital in the Tohoku region of Japan. The study was approved by the Institutional Review Board of each TGCU participant center.
A total of 23 patients were analyzed at TGCU (Table 1) . First treatment started between 1988 and 2006. Their median age at the first operation was 65 years old (range 38-83). The most common initial complaint was abdominal distension or pain (18/23; 78%). Two out of 23 patients had a history of malignancy. One patient (patient 23) had a past history of lung cancer four years before the treatment, and the other patient (patient 20) was diagnosed with lung cancer 13 months after the initial operation for PMP.
In this study, we defined PMP as a condition characterized by the accumulation of abundant mucinous material within the peritoneal cavity, often accompanied by ovarian or gastrointestinal tumor. PMP patients were sought as far back in time as possible (maximum of 20 years).
Clinical and follow-up data were retrieved in FileMaker (FileMaker, Inc., Santa Clara, CA, USA) based on the electronic format from each hospital. Clinico patho logical data retrieved were as follows: age at initial treatment, chief complaint at first visit, past his- Those with macroscopic lesion. For example, App § represents appendix with macroscopic lesion. ¶ Bilateral salpingo-oophorectomy was performed because of mucinous cystoadenoma of right ovary and serous cystadenoma of left ovary, 9 years before. tory of malignancy, FIGO ovarian cancer staging (borderline tumor or cancer), pathological diagnosis, estimated origin of tumor, appendiceal lesion, peritoneal cytology, date of initial operation, operation time, estimated blood loss, organ or tissue that was extirpated or left over with or without lesion, distribution of mucin, peritoneal lavage with dextrose, distribution of residual tumor, maximal diameter of residual tumor, serious complication within 30 days after operation, adjuvant chemotherapy (root and regimen), follow-up plan, date of recurrence, diagnosis of recurrence, site of recurrence, date of death, and cause of death. Overall/progression-free survival was calculated as the time difference between date of initial treatment and date of death/recurrence.
All slides from the surgical specimens were sent to one of the authors (M.T.) for central pathology review (CPR). Histopathological diagnoses were based on the World Health Organization Classification of Tumours (Tavassoli and Devilee 2003) . Borderline histology was defined as a tumor exhibiting an epithelial proliferation of mucinoustype cells greater than that seen in their benign counterparts but without destructive stromal invasion (Fig. 1) . In this study, the origin of PMP was diagnosed as appendiceal if there was concomitant appendiceal tumor with the same histology or if the tumor cells were tall.
Most of the patients were followed up every 1-3 months by internal examination, ultrasonography, and tumor markers. The tumor markers used for the follow up were carcinoembryonic antigen (CEA) (15/23; 65%), carbohydrate antigen (CA) 125 (12/23; 52%), and CA19-9 (11/23; 48%). In nearly half of the patients (9/23; 39%), a panel of CEA, CA125, and CA19-9 was used. A CT scan was performed every 6-12 months in most patients (15/23; 65%).
All statistical analyses were carried out using the Statistical Analysis System, Version 9.1 (SAS Institute Inc., Cary, NC, USA). To analyze the candidate prognostic factors, survival curves were derived using the Kaplan-Meier method and were compared using the log-rank test. Multivariate analysis was performed to detect independent prognostic factors. PROC LIFETEST, PROC GPLOT, and PROC PHREG in the SAS program were used. P values of < 0.05 were considered statistically significant.
Results
CPR revealed that 19 out of 23 patients were of borderline histology. Eighteen patients were of appendiceal origin, one was of rectal origin, one was of ovarian origin, and the other three were of equivocal ovarian or appendiceal origin (Table 1) .
The median follow-up period of 23 patients was 46 months (range 7-186). There were 13 recurrences or progressions in this period. Among these 13 patients, 7 patients died, and 2 patients were successfully treated and were free of disease at 80 and 82 months after initial treatment (patients 7 and 8). The remaining 10 patients were free of disease or progression at last follow up (Table 2) . Among 23 patients, 3 patients were untraceable after the last follow up at 27, 70, and 98 months (patients 3, 5, and 9). All recurrence and progression occurred within the peritoneal cavity. Among these cases, three patients also had vaginal cuff lesions. The median progression-free period was 30 months and that of overall survival was 166 months (Fig. 2) . Tables 1 and 2 summarize the treatment of these 23 patients. Eleven patients (48%) had no macroscopic residual disease after their operation. Optimal operation with a residual tumor with a diameter of 1 cm or less was performed in 3 patients. The other 9 patients had a suboptimal operation with a diameter over 1 cm (Table 2) .
Appendectomy was not performed in 8 patients (35%); of these, 6 were without macroscopic appendiceal lesions. In 3 patients with an ovarian lesion (patients 8, 12 and 13), unilateral salpingo-oophorectomy was performed, and one patient (patient 8) had a recurrence in the preserved ovary and was treated by salpingo-oophorectomy 38 months after the initial surgery.
Pelvic and para-aortic lymphoadenectomies were carried out in 9 and 3 patients, respectively, with no evidence of metastasis. The median operation time was 172 min Stromal invasion is not present. The epithelial cells exhibit slight to moderate atypia, and are stratified into two or three layers (Arrow). (range 60 -410 min), and the median estimated blood loss was 404 mL (10-3,700 mL). There were no patients who received HIPEC or cytoreduction with peritonectomy according to the method of Sugarbaker et al. (1995 Sugarbaker et al. ( , 2006 . Two patients had complications within 30 days of the operation: one with ileus and anemia (patient 6), the other with pelvic inflammation (patient 1). Intraoperative and/or adjuvant chemotherapy was given to 16 patients. Among 8 patients who received systemic chemotherapy, 7 recieved a combination of taxane and carboplatin. Eight patients received intraperitoneal chemotherapy with a wide variety of regimens: 4 were administered cisplatin, 3 patients mitomycin C, and 2 patients 5-fluorouracil.
Log-rank test revealed that the residual tumor diameter was a statistically significant prognostic factor (P = 0.022) (Fig. 3) . Log-rank test also revealed that, although systemic chemotherapy did not improve patient prognosis (P = 0.48), intra-peritoneal chemotherapy tended to improve the prog- ADM, adriamycin; App, appendix; AWD, alive with disease; CBDCA, carboplatin; CDDP, cisplatin; CPA, cyclophosphamide; DOC, docetaxel; DOD, dead of disease; 5-FU, 5-fluorouracil; IA, intra-abdominal; MMC, mitomycin C; NED, no evidence of disease; Om, omentum; P, peritoneal dissemination; PTX, paclitaxel; UFT, tegafur-uracil, VC, vaginal cuff.
*Administered by intra-peritoneal root. †
Recurrence at left ovary and treated by left salpingo-oophorectomy. ‡ Mucinous ascites was surgically removed and intraperitoneal CDDP and OK-432 were each administered for two episodes of progression (at 6 months and 12 months after initial treatment). § Not described in operation record, estimated from preoperative CT. || Administered for lung cancer, which was diagnosed 13 months after initial treatment for pseudomyxoma peritonei. There is a significant difference in survival between the patients with no visible tumor and those with macroscopic residual tumor (log-rank test: P = 0.022).
nosis compared with either systemic or no chemotherapy (P = 0.064) (Fig. 4) . Multivariate analysis revealed that the only independent prognostic factor was the residual tumor volume.
Discussion
We retrospectively analyzed a total of 23 patients with PMP who were initially treated by gynecologic oncologists because of the presence or past history of ovarian lesions.
Recent morphological, immunohistochemical, and molecular genetic studies (Ronnett et al. 1997; Szych et al. 1999 ) have provided compelling evidence that virtually all PMP lesions are derived from an appendiceal mucinous tumor and that any ovarian involvement is secondary (Ronnet et al. 2004 ). Ronnett et al. reported a clinicopathologic analysis of 30 patients with PMP: 28 (93.3%) of them had primary mucinous appendiceal or colonic tumors (Ronnett et al. 1995) . In our patients, there was only one case of ovarian origin, three were of equivocal ovarian or appendiceal origin, one was of rectal origin and the other 18 were of appendiceal origin. We classified those with tall cells or those with appendiceal and ovarian lesions that had the same histology as of appendiceal origin. Because this study is retrospective in nature, the macroscopic appearance of ovary or appendix could not be assessed in some patients, which made it difficult to apply Ronnett's criteria (Ronnett et al. 1995) , which might discriminate ovarian tumors associated with PMP from primary ovarian tumor.
The reported prognostic factors of PMP are age (Lee et al. 2008) , histology, residual tumor volume (Miner et al. 2005; Baratti et al. 2008) , and intraperitoneal chemotherapy (Gough et al. 1994 ). In our study, age at operation and histology were not prognostic factors, which was probably due to the small sample size of our study. Because most of the patients were diagnosed by CPR as having borderline histology (19/23), we could not assess the histology as a prognostic factor (P = 0.24).
Patients with no macroscopic residual tumor had a better prognosis (P = 0.022) (Fig. 3) . Multivariate analysis revealed that the only independent prognostic factor was the residual tumor diameter. We also assessed the prognostic factors among the 19 patients with borderline histology, and obtained similar trends that the residual tumor diameter was the only prognostic factor (data not shown).
Although systemic chemotherapy did not affect the prognosis, those who received intra-peritoneal treatment tended to have a better prognosis than those who received systemic chemotherapy or no chemotherapy (Fig. 4) . Because the regimens of intra-peritoneal chemotherapy were not identical, we did not further assess each regimen. A report detailing 97 cases from the Memorial SloanKettering Cancer Center revealed that there was no significant difference in survival irrespective of whether systemic chemotherapy was added (Miner et al. 2005) . In a report from the Mayo Clinic on a subgroup analysis of 31 patients with incomplete surgical removal of mucus, intra-abdominal chemotherapy significantly reduced the recurrence (Gough et al. 1994) . Our data are consistent with the results in these two reports: chemotherapy may improve survival only if administered intraperitonealy.
The result that the residual tumor volume affects the survival and that intraperitoneal chemotherapy marginally improves the survival may support the rationale of Sugarbaker's method, which consists of ultra-radical cytoreductive surgery with extreme peritoneal stripping (Sugarbaker 1995) and hyperthermic intra-abdominal chemotherapy (HIPEC). The follow-up data of 168 patients treated with this method at Washington Hospital Center show 10-year survival of 81% (Esquivel and Sugarbaker 2000) . Although the prognosis of PMP is improved by Sugarbaker's method, the operation is a complex procedure that requires special equipment and much more time (6-12 hours), and is also highly invasive, resulting in high operative morbidity (42%) and mortality (2.4%) (Yan et al. 2007) .
There were no patients treated by Sugarbaker's method in our study, probably because it is not popular in Japan. Thirteen out of 23 patients were treated with bilateral salpingo-oophorectomy and appendectomy. The operation was completed for half of our patients (11/23) with no macroscopic residual tumors. The median operation time was 172 min, the median estimated blood loss was 404 mL, only two out of 23 patients (8.7%) had major postoperative complications, and no patient died within 30 days of the operation.
The estimated 10-year survival rate for those with no residual tumor is approximately 80% (Fig. 3) . This is comparable to the results in a report from the Memorial SloanKettering Cancer Center (Miner et al. 2005) .
Even in patients without macroscopic lesions, univariate analyses could not detect a significant advantage of contralateral oophorectomy (P = 0.65), appendectomy (P = Fig. 4 . Effect of intraperitoneal chemotherapy on survival.
Patients with intraperitoneal chemotherapy tended to have better prognosis than those with no chemotherapy or those with systemic chemotherapy only (log-rank test: P = 0.064).
0.29), omentectomy (P = 0.29), or hysterectomy (P = 0.48).
As far as we know, there is no study that has investigated whether appendectomy improves the prognosis of PMP. The result that appendectomy was not a prognostic factor seems curious, since almost all PMP arises from the vermiform appendix (Ronnett et al. 2004 ). In the literature, 14 to 91 percent of patients had a resected vermiform appendix (Gough et al. 1994; Miner et al. 2005; Baratti et al. 2008) . In other words, up to 86% of PMP patients had not undergone resection of vermiform appendix. Despite the limitations of the small sample size and the retrospective nature, we are able to show that the macroscopic residual tumor is an important prognostic factor in Japanese women with PMP.
